by | May 21, 2024 | Publications
J Cancer Res Clin Oncol. 2024 May 20;150(5):266. doi: 10.1007/s00432-024-05800-8. ABSTRACT PURPOSE: Carfilzomib, commonly used for relapsed/refractory multiple myeloma (RRMM), has been associated with various adverse events in randomized controlled trials (RCTs)....
by | May 21, 2024 | Publications
Transplant Cell Ther. 2024 May 18:S2666-6367(24)00413-5. doi: 10.1016/j.jtct.2024.05.016. Online ahead of print. ABSTRACT BACKGROUND: Most transplant-eligible multiple myeloma (MM) patients undergo autologous peripheral blood stem cell collection (PBSC) using G-CSF...
by | May 20, 2024 | Publications
Blood. 2024 May 20:blood.2024024371. doi: 10.1182/blood.2024024371. Online ahead of print. ABSTRACT Estimating progression-free survival (PFS) and overall survival (OS) superiority during clinical trials of multiple myeloma (MM) has become increasingly challenging as...
by | May 20, 2024 | Publications
Blood Adv. 2024 May 20:bloodadvances.2024012967. doi: 10.1182/bloodadvances.2024012967. Online ahead of print. ABSTRACT HBI0101 is an academic chimeric antigen receptor T (CART) targeted to BCMA for the treatment of relapsed and refractory multiple myeloma (RRMM) and...
by | May 20, 2024 | Publications
Hematology. 2024 Dec;29(1):2352687. doi: 10.1080/16078454.2024.2352687. Epub 2024 May 20. ABSTRACT OBJECTIVE: Examine Bach1 protein expression in bone marrow biopsy specimens obtained from newly diagnosed multiple myeloma (NDMM) and iron deficiency anemia (IDA)...
by | May 20, 2024 | Publications
Transplant Cell Ther. 2024 May 17:S2666-6367(24)00408-1. doi: 10.1016/j.jtct.2024.05.011. Online ahead of print. NO ABSTRACT PMID:38763416 | DOI:10.1016/j.jtct.2024.05.011
